Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation

Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis

NCT04855617 ·Status: COMPLETED

Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study

NCT05285904 ·Status: COMPLETED

Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen

NCT04940065 ·Status: COMPLETED

ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients

NCT06345157 ·Status: ACTIVE_NOT_RECRUITING

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

NCT05906992 ·Status: RECRUITING ·Phase: PHASE3

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

NCT04035005 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment

NCT05171972 ·Status: COMPLETED

An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment

NCT06675955 ·Status: RECRUITING ·Phase: PHASE3

Characterizing the Use of Ofatumumab in a Real World Setting

NCT05090033 ·Status: COMPLETED

Mechanistic Study of Ocrevus

NCT04459988 ·Status: COMPLETED

A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data

NCT06854341 ·Status: COMPLETED

Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study

NCT06486779 ·Status: RECRUITING

Effects of Ocrevus in Relapsing Multiple Sclerosis

NCT04387734 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504 ·Status: RECRUITING ·Phase: PHASE3

A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)

NCT00239655 ·Status: TERMINATED ·Phase: PHASE2

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

NCT07207148 ·Status: RECRUITING

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

NCT06846281 ·Status: RECRUITING ·Phase: PHASE3

A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab

NCT06460324 ·Status: COMPLETED

A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)

NCT06780150 ·Status: RECRUITING

Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial

NCT05999604 ·Status: RECRUITING ·Phase: PHASE3

Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis

NCT03593590 ·Status: COMPLETED

Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)

NCT00395317 ·Status: COMPLETED ·Phase: PHASE2

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

NCT07325292 ·Status: RECRUITING ·Phase: PHASE3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

NCT04544436 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients

NCT06897657 ·Status: COMPLETED